Drug Reduces Mysterious Particle Involved in Heart Attack Risk
The Eli Lilly drug caused a major drop in the blood levels of Lp(a), but further research is needed to show that it will ...
Eli Lilly Phase 2 Lipoprotein(a) Study Hits Primary Endpoint
Eli Lilly on Sunday said the Phase 2 study of lepodisiran, designed to lower the production of lipoprotein (a), or lp (a), met its primary endpoint, reducing lp (a) levels by an average of 93.9% over ...
Experimental Lilly drug cuts genetic heart disease risk factor by 94% in trial
No serious adverse events related to the drug were reported. "What we have is a drug that can lower lipoprotein(a) with very ...
Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer
The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...
Eli Lilly launches weight-loss drug Mounjaro in India, beats Novo Nordisk to major market
Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...